Welcome to our dedicated page for Modular Medical SEC filings (Ticker: MODD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Modular Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Modular Medical's regulatory disclosures and financial reporting.
Modular Medical, Inc. director Ellen O'Connor Vos received a grant of options to purchase 250 shares of common stock at an exercise price of $4.88 per share. The options were granted under the Outside Director Compensation Plan, were fully vested and exercisable on the grant date, and expire on June 30, 2036.
Modular Medical, Inc. director Philip Brent Sheibley received an option grant covering 250 shares of common stock. The option was granted under the company’s Outside Director Compensation Plan, is fully vested, and became exercisable on the grant date at an exercise price of $4.88 per share.
Modular Medical, Inc. director Jeff D. Goldberg received an option grant to purchase 250 shares of common stock. The option was awarded on June 30, 2026 under the company’s Outside Director Compensation Plan, with an exercise price of $4.88 per share, and was fully vested and exercisable on the grant date. The option for 250 underlying common shares expires on June 30, 2036, and represents his reported beneficial ownership of this class of derivative security following the transaction.
Modular Medical, Inc. director Steven G. Felsher received equity compensation consisting of common shares and stock options. He was granted 25 shares of common stock at a stated price of $0.0000 per share under the company’s Outside Director Compensation Plan, bringing his direct common stock holdings to 8,498 shares.
He was also granted an option to purchase 250 shares of common stock at an exercise price of $4.88 per share, expiring on June 30, 2036. The option was fully vested and exercisable on the grant date. Share amounts reflect a 1-for-30 reverse stock split of the company’s common stock effected on March 31, 2026.
Modular Medical, Inc. director Carmen B. Volkart received a grant of common stock as part of board compensation. On the reported date, Volkart acquired 110 shares of common stock at a price of $0.00 per share, increasing direct holdings to 916 shares. The shares were issued under the company’s Outside Director Compensation Plan, and the reported share amounts reflect the impact of a 1-for-30 reverse stock split of the common stock that was effected on March 31, 2026.
Modular Medical, Inc. director Duane M. DeSisto received a grant of common stock under the company’s Outside Director Compensation Plan. He acquired 83 shares at a price of $0.00 per share and now directly holds 8,627 common shares. A 1-for-30 reverse stock split on March 31, 2026 affected the reported share amounts.
Modular Medical, Inc. director and 10% owner C. Frank Morgan received new stock option awards as part of his outside director compensation. On June 30, 2026, he was granted options for 250 shares of common stock and a separate grant for 62 shares, each with an exercise price of $4.88 per share. The footnotes state these options were granted under the company’s Outside Director Compensation Plan and were fully vested and exercisable on the grant date. Following the grants, his reported beneficial ownership for these option classes is 312 options for one class and 62 options for the other.
Modular Medical is an early commercial-stage diabetes device company focused on simple, low-cost insulin pumps for “Almost Pumpers” who currently rely on multiple daily injections. The company received FDA clearance for its original MODD1 pump in September 2024 and for its next‑generation Pivot patch pump in April 2026, but plans to commercialize only Pivot.
Pivot is a tubeless, 3 mL patch pump designed to be easier to learn and cheaper to manufacture, using contract production through Phillips Medisize. Initial U.S. shipments began in June 2026, with plans to expand across metropolitan markets by late 2026 and pursue CE mark clearance by the second quarter of 2027 for European and other markets.
Financially, the company remains under significant strain. As of March 31, 2026, it reported cash and cash equivalents of $6.9 million and an accumulated deficit of $113.0 million. It closed an additional public offering in April 2026 for about $3.0 million, yet management states this will still not fund operations for the next 12 months. Net losses were approximately $28.2 million in fiscal 2026 and $18.8 million in fiscal 2025, and the filing explicitly raises substantial doubt about the company’s ability to continue as a going concern without further capital.
Modular Medical, Inc. disclosed new stock option awards for two senior executives. On May 14, 2026, the board granted 11,218 stock options to Chairman, President, Chief Financial Officer and Treasurer Paul DiPerna and 4,674 stock options to Chief Operating Officer Kevin Schmid.
The options carry an exercise price of $3.46 per share, vest with one-third of the shares on May 14, 2027 and the remaining shares vesting monthly over the following 24 months, contingent on continued service. The options expire on May 14, 2036 and were issued under the company’s Amended and Restated 2017 Equity Incentive Plan.
Modular Medical, Inc. reported that company officer Paul DiPerna received a grant of stock options as part of his compensation. He was awarded options to purchase 11,218 shares of common stock at an exercise price of $3.46 per share, expiring on May 14, 2036. One third of the options will vest on May 14, 2027, with the remaining portion vesting in equal monthly installments over the following 36 months. After this grant, DiPerna holds 11,218 options of this class directly.